Catyalyst Pharma (CPRX) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results
March 15, 2016 4:30 PM EDTCORAL GABLES, Fla., March 15, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the fourth quarter and the year-ended December 31, 2015.
"2015 was a year of many accomplishments for Catalyst as we progressed with our NDA submission for Firdapse®, as well as the expansion of our product pipeline to include other potential indications for Firdapse," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "As we work to resolve the regulatory... More
